Full Press Release Details
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First in Class PARG Inhibitor Targeting HRD Solid Tumors.
IDYA
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First in Class PARG Inhibitor Targeting HRD Solid Tumors
Key Takeaway: IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First in Class PARG Inhibitor Targeting HRD Solid Tumors
Price reaction · baseline $14.89 (2023-04-18 close) · hit after-hours · 2 other IDYA headline(s) in the window, move may be shared
day 0 close
-0.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma